Main Article Content
Objective: Detection of minor (p190) BCR-ABL fusion protein in a CML patients.
Case Report: A 26-year-old female presented with complaints of pain abdomen and episodes of vomiting. On examination her vitals were stable and there was moderate splenomegaly. The peripheral blood and bone marrow cytological features were consistent with myeloproliferative neoplasm. Fluorescent in situ hybridization (FISH) for BCR ABL was positive, with 87% of cells showing fusion transcript. However, Real Time Polymerase chain reaction (RT-PCR) for p210 BCR-ABL was found to be negative. In view of high morphologic index of suspicion for CML, further molecular analysis was carried out for BCR/ABL fusion transcript variants along with JAK2 V617F mutations.
Conclusion: The patient was found to be positive for BCR/ABL p190 e1a2 fusion transcript, while BCR/ABL p210 fusion transcript was negative.
Ismail SI, Naffa RG, Yousef AM, Ghanim MT. Incidence of bcr abl fusion transcripts in healthy individuals. Mol Med Rep. 2014; 9:1271-6.
Xue M, Wang Q, Huo L, Wen L, Yang X, Wu Q et al. Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts. Leuk Lymphoma. 2019;1:1-7.
Baccarani M, Castagnetti F, Gugliotta G, Rosti G, Soverini S, Albeer A, Pfirrmann M. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview. Leukemia. 2019;33:1173-1183.
Gong Z, Medeiros LJ, Cortes JE, Zheng L, Khoury JD, Wang W et al. Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia. Blood Cancer J. 2017;7:e583.
Verma D, Kantarjian HM, Jones D, Luthra R, Borthakur G, Verstovsek S, et al. Chronic myeloid leukemia (CML) with P190 BCR-ABL: Analysis of characteristics, outcomes, and prognostic significance. Blood. 2009;114:2232-5.
Yaghmaie M, Ghaffari SH, Ghavamzadeh A, Alimoghaddam K, Jahani M, Mousavi SA, et al. Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloidleukemia. Arch Iran Med. 2008; 11:247-51.
Goh HG, Hwang JY, Kim SH, Lee YH, Kim YL, Kim DW. Comprehensive analysis of BCR-ABL transcript types in Korean CML patients using a newly developed multiplex RT-PCR. Transl Res. 2006;148:249- 56.
Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343-56.
Score J, Calasanz MJ, Ottman O, Pane F, Yeh RF, Sobrinho-Simões MA, et al. Analysis of genomic breakpoints in p190 and p210 BCR–ABL indicate distinct mechanisms of formation. Leukemia. 2010;24:1742-50.
Li S, Ilaria RL Jr, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med. 1999;189:1399–1412.
Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Recommendations from an expert panel on behalf of European Leukemia Net. Blood. 2011;118:1208-15.
Ohsaka A, Shiina S, Kobayashi M, Kudo H, Kawaguchi R. Philadelphia chromosome-positive chronic myeloid leukemia expressing p190 (BCR-ABL). Intern Med. 2002;41:1183-7.
Andrikovics H, Nahajevszky S, Szilvási A, Bors A, Adám E, Kozma A et al. First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts. Hematol Oncol. 2007;25:143-7.
Radojkovic M, Ristic S, Pavlovic S, Colovic M. Molecular response to imatinib in patient with Ph negative p190 BCR-ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis. Leuk Res. 2009;33:10-2.